Results 11 to 20 of about 124,717 (304)

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

New England Journal of Medicine, 2016
Immune checkpoint inhibitors have improved clinical outcomes associated with numerous cancers, but high-grade, immune-related adverse events can occur, particularly with combination immunotherapy. We report the cases of two patients with melanoma in whom fatal myocarditis developed after treatment with ipilimumab and nivolumab.
Douglas B, Johnson, Justin M, Balko, Margaret L, Compton, Spyridon, Chalkias, Joshua, Gorham, Yaomin, Xu, Mellissa, Hicks, Igor, Puzanov, Matthew R, Alexander, Tyler L, Bloomer, Jason R, Becker, David A, Slosky, Elizabeth J, Phillips, Mark A, Pilkinton, Laura, Craig-Owens, Nina, Kola, Gregory, Plautz, Daniel S, Reshef, Jonathan S, Deutsch, Raquel P, Deering, Benjamin A, Olenchock, Andrew H, Lichtman, Dan M, Roden, Christine E, Seidman, Igor J, Koralnik, Jonathan G, Seidman, Robert D, Hoffman, Janis M, Taube, Luis A, Diaz, Robert A, Anders, Jeffrey A, Sosman, Javid J, Moslehi   +31 more
openaire   +4 more sources

Radiotherapy Complements Immune Checkpoint Blockade [PDF]

Cancer Cell, 2015
Adaptive immune resistance ablates effective anti-tumor immune responses. In a recent issue of Nature, Victor and colleagues describe that anti-PD-L1 combats adaptive immune resistance upon localized radiation plus anti-CTLA-4 therapy. The superior activity of radiation and dual immune checkpoint blockade is mediated by non-redundant immune mechanisms ...
Ngiow, Shin Foong, McArthur, Grant A., Smyth, Mark J.   +2 more
openaire   +3 more sources

Myocarditis with Immune Checkpoint Blockade [PDF]

New England Journal of Medicine, 2017
In their discussion of fulminant myocarditis and complete heart block during immune checkpoint therapy, Johnson et al. do not discuss the possible role of circulating anticonductive tissue autoantibodies (ACTA) in the pathogenesis of the sudden heart block and myocarditis.1 Since it is not known which autoantigens (other than troponin I, which was ...
Javid J, Moslehi, Douglas B, Johnson, Jeffrey A, Sosman   +2 more
openaire   +5 more sources

Enhancing the efficacy of immunotherapy using radiotherapy

Clinical & Translational Immunology, 2020
Recent clinical breakthroughs in cancer immunotherapy, especially with immune checkpoint blockade, offer great hope for cancer sufferers – and have greatly changed the landscape of cancer treatment.
Synat Keam, Suki Gill, Martin A Ebert, Anna K Nowak, Alistair M Cook   +4 more
doaj   +1 more source

Renal complications of immune checkpoint blockade [PDF]

Current Problems in Cancer, 2017
Immune checkpoint inhibitors have been approved for a variety of cancer species. Renal complications in use of these agents are not very common compared with other immune-related adverse events (irAE). However, it is crucial for physicians to recognize and manage renal manifestations of irAE.
Naoka, Murakami, Shveta, Motwani, Leonardo V, Riella   +2 more
openaire   +2 more sources

Immune-Checkpoint Blockade Therapy in Lymphoma [PDF]

International Journal of Molecular Sciences, 2020
Tumor cells use immune-checkpoint pathways to evade the host immune system and suppress immune cell function. These cells express programmed cell-death protein 1 ligand 1 (PD-L1)/PD-L2, which bind to the programmed cell-death protein 1 (PD-1) present on cytotoxic T cells, trigger inhibitory signaling, and reduce cytotoxicity and T-cell exhaustion ...
Ayumi Kuzume, SungGi Chi, Nobuhiko Yamauchi, Yosuke Minami   +3 more
openaire   +2 more sources

Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma

Biomedicines, 2022
Malignant pleural mesothelioma (MPM) is a fatal cancer type that affects the membranes lining the lungs, and is causally associated with asbestos exposure. Until recently, the first-line treatment consisted of a combination of chemotherapeutics that only
Sophie Rovers, Annelies Janssens, Jo Raskin, Patrick Pauwels, Jan P. van Meerbeeck, Evelien Smits, Elly Marcq   +6 more
doaj   +1 more source

Smoldering myocarditis following immune checkpoint blockade [PDF]

Journal for ImmunoTherapy of Cancer, 2017
Severe myocarditis associated with electrical conduction abnormalities and occasionally heart failure has been well documented following treatment with immune checkpoint blockade with an estimated incidence of less than 1%. However, the incidence, early detection, and management of less severe immune-related myocarditis are unknown since most ...
Timothy G. Norwood, Brian C. Westbrook, Douglas B. Johnson, Silvio H. Litovsky, Nina L. Terry, Svetlana B. McKee, Alan S. Gertler, Javid J. Moslehi, Robert M. Conry   +8 more
openaire   +5 more sources

Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity

Journal of Experimental & Clinical Cancer Research, 2021
Immune checkpoint inhibitors provide considerable therapeutic benefit in a range of solid cancers as well as in a subgroup of hematological malignancies.
Allan Relecom, Maysaloun Merhi, Varghese Inchakalody, Shahab Uddin, Darawan Rinchai, Davide Bedognetti, Said Dermime   +6 more
doaj   +1 more source

Programmed Cell Death Protein 1 Axis Inhibition in Viral Infections: Clinical Data and Therapeutic Opportunities

Vaccines, 2022
A vital function of the immune system is the modulation of an evolving immune response. It is responsible for guarding against a wide variety of pathogens as well as the establishment of memory responses to some future hostile encounters. Simultaneously,
Konstantinos Tsiakos, Niki Gavrielatou, Ioannis A. Vathiotis, Loukas Chatzis, Stamatios Chatzis, Garyfallia Poulakou, Elias Kotteas, Nikolaos K. Syrigos   +7 more
doaj   +1 more source